Intrinsiqq
Viracta Therapeutics, Inc. logo

Viracta Therapeutics, Inc. Financials

VIRX

Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 6 of 16 available years
Income Statement
TTM
DEC 2023
DEC 2022
DEC 2021
~2.3:1 split
DEC 2020
DEC 2019
~2.4:1 split
Revenues
Revenue$0–––$0$2
General & Administrative$5$17$24$15$5$10
Research & Development$13$33$26$24$13$15
Total Operating Expenses$19$51$51$128$19$25
Operating Income-$19-$51-$51-$114-$19-$23
Non-Operating
Net Interest Expense-$0-$4-$1-$0-$0-$1
Other Non-Operating Income (Expense)-$0-$0$1-$0-$3$0
EBT (Earnings Before Tax)––––-$22-$23
Income Tax Expense–$0$0$0$0$0
Net Income
Net Income-$19-$51-$49-$115-$19-$23
Per Share Data
Revenue Per Share$0.01–––$0.01$0.02
EPS (Basic)-$1.35-$1.32-$1.30-$3.60-$1.35-$0.27
EPS (Diluted)-$1.35-$1.32-$1.30-$3.60-$1.35-$0.27
Weighted Avg Shares (Basic)14.1M38.6M37.8M31.9M14.1M87.1M
Weighted Avg Shares (Diluted)14.1M38.6M37.8M31.9M14.1M87.1M
Shares Outstanding14.1M38.6M37.8M31.9M14.1M87.1M

Viracta Therapeutics (VIRX) financials: revenue, profit and margins

Viracta Therapeutics (VIRX) generated about n/a in revenue and -$43 million in net income over the trailing twelve months, growing at roughly -47.7% a year. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Viracta Therapeutics profitable?+

Viracta Therapeutics reported about -$43 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How fast is Viracta Therapeutics growing?+

Viracta Therapeutics's revenue has compounded at roughly -47.7% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside VIRX's margins and free cash flow. This is analysis from SEC filings, not investment advice.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 11 Nov 2024, covering the period ending 30 Sept 2024, as reported to the SEC. Data last refreshed 14 Aug 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Pharmaceutical Preparations · Pick stocks to compare with VIRX

CompareIntrinsic value
ABBVAbbVie Inc.
$286.20+0.94%49
SKVISkinvisible Inc.
$0.18+0.00%0
SILOSilo Pharma Inc.
$1.73-7.98%10
CAMPCamp4 Therapeutics Corp.
$3.79-5.25%40
RANIRani Therapeutics Holdings Inc.
$0.51-12.03%10
HYPDHyperion DeFi, Inc.
$2.08-11.11%50
SERSerina Therapeutics Inc.
$1.12-6.67%40
DAREDare Bioscience Inc.
$0.41-9.96%10

Spot a number that looks wrong? Check it in VIRX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing VIRX

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.